$18.78
0.81% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US45781M1018
Symbol
INVA

Innoviva Stock price

$18.78
+0.50 2.74% 1M
-0.37 1.93% 6M
+1.43 8.24% YTD
+2.65 16.43% 1Y
+2.49 15.29% 3Y
+4.68 33.19% 5Y
+2.54 15.64% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.15 0.81%
ISIN
US45781M1018
Symbol
INVA
Sector
Industry

Key metrics

Market capitalization $1.18b
Enterprise Value $1.18b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 5.92
EV/Sales (TTM) EV/Sales 3.08
P/S ratio (TTM) P/S ratio 3.07
P/B ratio (TTM) P/B ratio 1.82
Revenue growth (TTM) Revenue growth 17.90%
Revenue (TTM) Revenue $383.64m
EBIT (operating result TTM) EBIT $182.49m
Free Cash Flow (TTM) Free Cash Flow $199.99m
Cash position $446.88m
EPS (TTM) EPS $-1.00
P/E forward 28.03
P/S forward 3.23
EV/Sales forward 3.24
Short interest 19.14%
Show more

Is Innoviva a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Innoviva Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Innoviva:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Innoviva:

Buy
100%

Financial data from Innoviva

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
384 384
18% 18%
100%
- Direct Costs 74 74
9% 9%
19%
309 309
27% 27%
81%
- Selling and Administrative Expenses 73 73
3% 3%
19%
- Research and Development Expense 14 14
44% 44%
4%
222 222
50% 50%
58%
- Depreciation and Amortization 40 40
4% 4%
10%
EBIT (Operating Income) EBIT 182 182
66% 66%
48%
Net Profit -60 -60
133% 133%
-16%

In millions USD.

Don't miss a Thing! We will send you all news about Innoviva directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Innoviva Stock News

Neutral
Business Wire
about 18 hours ago
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced the United States commercial availability of ZEVTERA® (ceftobiprole medocaril sodium for injection), the newest addition to the Company's growing antibiotic portfolio. ZEVTERA is the only U.S. Food and Drug Administration (FDA) approved advanced-generation cepha...
Neutral
GlobeNewsWire
about 23 hours ago
Allschwil, Switzerland, May 20, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that its antibiotic Zevtera® (ceftobiprole medocaril for injection) is now commercially available in the United States through Basilea's partner Innoviva Special...
Neutral
Business Wire
13 days ago
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the first quarter ended March ...
More Innoviva News

Company Profile

Innoviva, Inc. is engaged in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

Head office United States
CEO Pavel Raifeld
Employees 127
Founded 1996
Website www.inva.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today